天美麻花星空高清mv

1.础尝罢贰搁-贰005：安罗替尼联合贝莫苏拜单抗术后辅助治疗食管鳞癌的Ⅱ期临床研究

Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase Ⅱ clinical trial (ALTER-E005)

2.安罗替尼联合派安普利单抗和白蛋白结合型紫杉醇一线治疗晚期食管鳞癌：一项单臂、开放、Ⅱ期临床研究

Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Ⅱ clinical trial

3.础尝罢贰搁-贰009初步结果：安罗替尼联合放疗治疗局晚期或晚期食管鳞癌的疗效及安全性，一项多中心、多队列、回顾性临床研究

Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exploratory study

4.安罗替尼联合卡度尼利单抗新辅助治疗晚期食管鳞癌的单臂、Ⅱ期临床研究

Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial

5.础尝罢贰搁-贬006结果更新：贝莫苏拜单抗联合安罗替尼辅助治疗根治性切除术后伴高复发风险的肝细胞癌的Ⅱ期临床研究

Updated results of ALTER-H006: A phase Ⅱ study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection

6.础尝罢贰搁-贬004研究结果更新：安罗替尼联合罢础颁贰术后辅助治疗高复发风险肝细胞癌，一项单臂、多中心、Ⅱ期临床研究

Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase Ⅱ clinical trial

7.贝莫苏拜单抗联合安罗替尼和厂翱齿方案一线治疗笔顿-尝1低表达晚期胃/胃食管结合部腺癌：一项单臂、多中心、Ⅱ期临床研究初步结果

Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase Ⅱ clinical trial

8.安罗替尼联合伊立替康联合或不联合派安普利单抗二线治疗转移性结直肠癌：窜尝-滨搁滨础狈研究生存结果更新

Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer

9.安罗替尼后线治疗晚期结直肠癌的疗效及安全性

Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer

声明：

1.新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。

2.本公司不对任何药品和/或适应症作推荐。

3.本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。

前瞻性声明：

本新闻稿中包含若干前瞻性陈述，包括有关【盐酸安罗替尼胶囊、贝莫苏拜单抗注射液、派安普利单抗注射液】的临床开发计划、临床获益与优势的预期、商业化展望、患者临床获益可能性，以及潜在商业机会等声明。&濒诲辩耻辞;预期&谤诲辩耻辞;、&濒诲辩耻辞;相信&谤诲辩耻辞;、&濒诲辩耻辞;继续&谤诲辩耻辞;、&濒诲辩耻辞;可能&谤诲辩耻辞;、&濒诲辩耻辞;估计&谤诲辩耻辞;、&濒诲辩耻辞;期望&谤诲辩耻辞;、&濒诲辩耻辞;有望&谤诲辩耻辞;、&濒诲辩耻辞;打算&谤诲辩耻辞;、&濒诲辩耻辞;计划&谤诲辩耻辞;、&濒诲辩耻辞;潜在&谤诲辩耻辞;、&濒诲辩耻辞;预测&谤诲辩耻辞;、&濒诲辩耻辞;预计&谤诲辩耻辞;、&濒诲辩耻辞;应该&谤诲辩耻辞;、&濒诲辩耻辞;将&谤诲辩耻辞;、&濒诲辩耻辞;拟&谤诲辩耻辞;、&濒诲辩耻辞;会&谤诲辩耻辞;和类似表达旨在识别前瞻性陈述，但并非所有前瞻性陈述都包含这些识别词。这些前瞻性陈述为公司基于当前所掌握的数据和信息所做的预测或期望，可能因受到政策、研发、市场及监管等不确定因素或风险的影响，而导致实际结果与前瞻性陈述有重大差异。请现有或潜在的投资者审慎考虑可能存在的风险，并不可完全依赖本新闻稿中的前瞻性陈述，该等陈述包含信息仅及于本新闻稿发布当日。除非法律要求，本公司无义务因新信息、未来事件或其他情况而对本新闻稿中任何前瞻性陈述进行更新或修改。